Trial · NCT02728089
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Microbiological Response of Eradication at Test of Cure (TOC) | Day 14 (14 days post first dose of study drug) | All participants who received at least 1 dose of study drug, had at least 1 acceptable causative uropathogen at baseline, adhered to study procedures, had a clinical response at the visit of interest within specified visit window, had an appropriately collected urine culture specimen and interpretable urine culture result at the visit of interest. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants Who Report 1 or More Adverse Event (AE) | Up to 42 days post first dose of study drug | All participants who received at least 1 dose of study treatment and had follow-up data for endpoint. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants Discontinuing Study Drug Due to an AE | Up to 7 days after the first dose of study drug | All participants who received at least 1 dose of study treatment and had follow-up data for endpoint. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Microbiological Response of Eradication at End Of Therapy (EOT) | Day 7 (7 days post first dose of study drug) | All participants who received at least 1 dose of study drug, had at least 1 acceptable causative uropathogen at baseline, adhered to study procedures, had a clinical response at the visit of interest within specified visit window, had an appropriately collected urine culture specimen and interpretable urine culture result at the visit of interest. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Microbiological Response of Eradication at Late Follow-up (LFU) | Day 42 (42 days post first dose of study drug) | All participants who received at least 1 dose of study drug, had at least 1 acceptable causative uropathogen at baseline, adhered to study procedures, had a clinical response at the visit of interest within specified visit window, had an appropriately collected urine culture specimen and interpretable urine culture result at the visit of interest. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Clinical Response of Clinical Cure at TOC | Day 14 (14 days post first dose of study drug) | All participants who received at least 1 dose of study treatment, had at least 1 acceptable causative uropathogen at baseline, adhered to study procedures and had a clinical response at the visit of interest within the specified visit window. All participants had to have an evaluable clinical outcome; an indeterminate response was excluded. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Clinical Response of Clinical Cure at EOT | Day 7 (7 days post first dose of study drug) | All participants who received at least 1 dose of study treatment, had at least 1 acceptable causative uropathogen at baseline, adhered to study procedures and had a clinical response at the visit of interest within the specified visit window. All participants had to have an evaluable clinical outcome; an indeterminate response was excluded. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Clinical Response of Clinical Cure at LFU | Day 42 (42 days post first dose of study drug) | All participants who received at least 1 dose of study treatment, had at least 1 acceptable causative uropathogen at baseline, adhered to study procedures and had a clinical response at the visit of interest within the specified visit window. All participants had to have an evaluable clinical outcome; an indeterminate response was excluded. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With a Composite Response of Both Eradication and Clinical Cure at TOC | Day 14 (14 days post first dose of study drug) | All participants who received at least 1 dose of study drug, had at least 1 acceptable causative uropathogen at baseline, adhered to study procedures, had a clinical response at the visit of interest within specified visit window, had an appropriately collected urine culture specimen and interpretable urine culture result at the visit of interest. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Microbiological Response of Eradication, by Pathogen at EOT | Day 7 (7 days post first dose of study drug) | All participants who received at least 1 dose of study drug, had at least 1 acceptable causative uropathogen at baseline, adhered to study procedures, had a clinical response at the visit of interest within specified visit window, had an appropriately collected urine culture specimen and interpretable urine culture result at the visit of interest. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Microbiological Response of Eradication by Pathogen at TOC | Day 14 (14 days post first dose of study drug) | All participants who received at least 1 dose of study drug, had at least 1 acceptable causative uropathogen at baseline, adhered to study procedures, had a clinical response at the visit of interest within specified visit window, had an appropriately collected urine culture specimen and interpretable urine culture result at the visit of interest. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Microbiological Response of Eradication by Pathogen at LFU | Day 42 (42 days post first dose of study drug) | All participants who received at least 1 dose of study drug, had at least 1 acceptable causative uropathogen at baseline, adhered to study procedures, had a clinical response at the visit of interest within specified visit window, had an appropriately collected urine culture specimen and interpretable urine culture result at the visit of interest. | Percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02728089/outcomes